472

40. Comparison of rifaximin and lactitil in the treatment of acute hepatic encephalopathy/A. Mas [et al.]//J. Hepatol. – 2003. – Vol. 38. – P. 51–58. 41.  Ishak, KG. Chronic hepatitis. Morphology and nomenclature/KG. Is- hak//Modern Pathol. – 1994. – V. 7. – P. 690–713. 42. de Franchis, R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension/R. de Franchis//J. Hepatology. – 2000. – V. 33. – P. 846–852. 43. Malchesky, P. S. Apheresis technologies: an international perspective /P. S. Malchesky, R. Bambauer, T. Horiuchi//Artificial organs. – 1995. –Vol. 19. – P. 56–67. 44. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC)/M. Primignani [et al.]//Gastroenterology. – 2000. – Vol. 119. – P.181–187. 45. Prevalence and natural history of subclinical hepatic encepha- lopathy in cirrhosis/A. Das [et al.]//J. Gastroenterol. Hepatol. – 2001. – Vol. 16. – P. 531–535. 46. Role of zinc in subclinical hepatic encephalopathy: comparison with somatosensory-evoked potentials/S. S. Yang [et al.]//J. of gastroenterol. and. hepatol. – 2004. – Vol. 19. – P. 375–379. 47.  Stanley,A. J. Portalhypertensionandvaricealhaemorrhage/A. J. Stanley, P. C. Hayes//Lancet. – 1997. – V. 350. – P. 1235–1239. 48. The morphology of cirrhosis: Definition, nomenclature and classification /P. P. Anthony [et al.]//Bull. WHO. – 1977. – V. 55. – P. 521–524. 49. The management of portal hypertension: Rational basis, available treatment and future options/J. Bosch [et al.]//J. Hepatol. – 2008. – Vol. 48. – P. 68–93. 50. Visual eventrelated P300 in early portosystemic encephalopathy/C. Kug- ler [et al.]//Gastroenterology. – 1992. – N 1. – P. 302–310.